Update on obinutuzumab in the treatment of B-cell malignancies

Bibliography

• Facts Spring 2014. 2014. Available from: http://www.lls.org/content/nationalcontent/resourcecenter/freeeducationmaterials/generalcancer/pdf/facts.pdf [cited 2014]
   Google Scholar
• Salles G, Seymour JF, Offner F. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011;377(9759):42-51
   PubMed Web of Science ®Google Scholar
• van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-hodgkin’s lymphoma: long-term outcome of the EORTC 20981 Phase III randomized intergroup study. J Clin Oncol 2010;28(17):2853-8
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376(9747):1164-74
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26(28):4579-86
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106(12):3725-32
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346(4):235-42
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Kuhnt E, Trumper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011;12(11):1013-22
   PubMed Web of Science ®Google Scholar
• Maloney DG. Immunotherapy for non-Hodgkin’s lymphoma: monoclonal antibodies and vaccines. J Clin Oncol 2005;23(26):6421-8
   PubMed Web of Science ®Google Scholar
• Cartron G, Trappe RU, Solal-Celigny P, Hallek M. Interindividual variability of response to rituximab: from biological origins to individualized therapies. Clin Cancer Res 2011;17(1):19-30
   PubMed Web of Science ®Google Scholar
• Lim SH, Beers SA, French RR, et al. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 2010;95(1):135-43
   PubMed Web of Science ®Google Scholar
• Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis: signalling through lipid rafts. Immunology 2002;107(2):176-82
   PubMed Web of Science ®Google Scholar
• Polyak MJ, Tailor SH, Deans JP. Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment. J Immunol 1998;161(7):3242-8
   PubMed Web of Science ®Google Scholar
• Cragg MS, Morgan SM, Chan HT, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003;101(3):1045-52
   PubMed Web of Science ®Google Scholar
• Chan HT, Hughes D, French RR, et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res 2003;63(17):5480-9
   PubMed Web of Science ®Google Scholar
• Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004;103(7):2738-43
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, de Vos S, Pohlman BL, et al. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcgammaRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res 2012;18(5):1395-403
   PubMed Web of Science ®Google Scholar
• Tobinai K, Ogura M, Kobayashi Y, et al. Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma. Cancer Sci 2011;102(2):432-8
   PubMed Web of Science ®Google Scholar
• Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177(1):362-71
   PubMed Web of Science ®Google Scholar
• Hollander N. Immunotherapy for B-cell lymphoma: current status and prospective advances. Front Immunol 2012;3:3
   Google Scholar
• Goldenberg DM, Rossi EA, Stein R, et al. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood 2009;113(5):1062-70
   PubMed Web of Science ®Google Scholar
• Le Garff-Tavernier M, Herbi L, de Romeuf C, et al. Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion. Leukemia 2014;28(1):230-3
   PubMed Web of Science ®Google Scholar
• Cheney CM, Stephens DM, Mo X, et al. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia. Mabs 2014;6(3):749-55
   PubMedGoogle Scholar
• Ivanov A, Beers SA, Walshe CA, et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest 2009;119(8):2143-59
   PubMed Web of Science ®Google Scholar
• Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010;115(22):4393-402
   PubMed Web of Science ®Google Scholar
• Robak T, Robak E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs 2011;25(1):13-25
   PubMed Web of Science ®Google Scholar
• Bowles JA, Wang SY, Link BK, et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 2006;108(8):2648-54
   PubMed Web of Science ®Google Scholar
• Breitmeyer J, Campbell MA, Allan B, et al. AME-133: a next-generation Anti-CD20 engineered for enhanced killer function. J Immunother 2004;27(6):S52-2
   Google Scholar
• Herter S, Herting F, Mundigl O, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther 2013;12(10):2031-42
   PubMed Web of Science ®Google Scholar
• Niederfellner G, Lammens A, Mundigl O, et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood 2011;118(2):358-67
   PubMed Web of Science ®Google Scholar
• Klein C, Lammens A, Schafer W, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. Mabs 2013;5(1):22-33
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc gamma RIIIa gene. Blood 2002;99(3):754-8
   PubMed Web of Science ®Google Scholar
• Persky DO, Dornan D, Goldman BH, et al. Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica 2012;97(6):937-42
   PubMed Web of Science ®Google Scholar
• Zhang W, Wang X, Li J, et al. Fc gamma receptor IIIA polymorphisms and efficacy of rituximab therapy on Chinese diffuse large B-cell lymphoma. Chin Med J(Engl) 2010;123(2):198-202
   PubMed Web of Science ®Google Scholar
• Kim DH, Du Jung H, Kim JG, et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 2006;108(8):2720-5
   PubMed Web of Science ®Google Scholar
• Ahlgrimm M, Pfreundschuh M, Kreuz M, et al. The impact of Fc-gamma receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab. Blood 2011;118(17):4657-62
   PubMed Web of Science ®Google Scholar
• Varoczy L, Zilahi E, Gyetvai A, et al. Fc-gamma-receptor IIIa polymorphism and gene expression profile do not predict the prognosis in diffuse large B-cell lymphoma treated with R-CHOP protocol. Pathol Oncol Res 2012;18(1):43-8
   PubMed Web of Science ®Google Scholar
• Prochazka V, Papajik T, Gazdova J, et al. Fc gamma RIIIA receptor genotype does not influence an outcome in patients with follicular lymphoma treated with risk-adapted immunochemotherapy. Neoplasma 2011;58(3):263-70
   PubMed Web of Science ®Google Scholar
• Carlotti E, Salmoiraghi S, Palumbo GA, et al. Fc alpha RIIIA and Fc Gamma RIIA polymorphisms do not predict the clinical outcome of follicular non Hodgkin’s lymphoma patients treated with sequential CHOP and Rituximab. Haematologica 2007;92:49-9
   Web of Science ®Google Scholar
• Mitrovic Z, Aurer I, Radman I, et al. FC gamma RIIIA and FC gamma RIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphorna. Haematologica 2007;92(7):998-9
   PubMed Web of Science ®Google Scholar
• Fabisiewicz A, Paszkiewicz-Kozik E, Osowiecki M, et al. Fc gamma RIIA and Fc gamma RIIIA polymorphisms do not influence survival and response to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy in patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2011;52(8):1604-6
   PubMed Web of Science ®Google Scholar
• Dornan D, Spleiss O, Yeh RF, et al. Effect of FCGR2A and FCGR3A variants on CLL outcome. Blood 2010;116(20):4212-22
   PubMed Web of Science ®Google Scholar
• Farag SS, Flinn IW, Modali R, et al. Fc gamma RIIIa and Fc-gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 2004;103(4):1472-4
   PubMed Web of Science ®Google Scholar
• Jaglowski SM, Alinari L, Lapalombella R, et al. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood 2010;116(19):3705-14
   PubMed Web of Science ®Google Scholar
• Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009;8(3):226-34
   PubMed Web of Science ®Google Scholar
• Ferrara C, Grau S, Jager C, et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci USA 2011;108(31):12669-74
   PubMed Web of Science ®Google Scholar
• Ferrara C, Stuart F, Sondermann P, et al. The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem 2006;281(8):5032-6
   PubMed Web of Science ®Google Scholar
• Shibata-Koyama M, Iida S, Okazaki A, et al. The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation. Glycobiology 2009;19(2):126-34
   PubMed Web of Science ®Google Scholar
• Mizushima T, Yagi H, Takemoto E, et al. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes Cells 2011;16(11):1071-80
   PubMed Web of Science ®Google Scholar
• Umana P, Moessner E, Bruenker P, et al. Novel 3(rd) generation humanized type IICD20 antibody with glycoengineered fc and modified elbow hinge for enhanced ADCC and superior apoptosis induction. Blood 2006;108(11):72a-a
   Google Scholar
• Kern DJ, James BR, Blackwell S, et al. GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present. Leuk Lymphoma 2013;54(11):2500-5
   PubMed Web of Science ®Google Scholar
• Patz M, Isaeva P, Forcob N, et al. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol 2011;152(3):295-306
   PubMed Web of Science ®Google Scholar
• Bologna L, Gotti E, Manganini M, et al. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol 2011;186(6):3762-9
   PubMed Web of Science ®Google Scholar
• Golay J, Da Roit F, Bologna L, et al. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood 2013;122(20):3482-91
   PubMed Web of Science ®Google Scholar
• Herter S, Birk MC, Klein C, et al. Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity. J Immunol 2014;192(5):2252-60
   PubMed Web of Science ®Google Scholar
• Dalle S, Reslan L, Besseyre de Horts T, et al. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther 2011;10(1):178-85
   PubMed Web of Science ®Google Scholar
• Alduaij W, Ivanov A, Honeychurch J, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011;117(17):4519-29
   PubMed Web of Science ®Google Scholar
• Jak M, van Bochove GG, Reits EA, et al. CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101. Blood 2011;118(19):5178-88
   PubMed Web of Science ®Google Scholar
• Alduaij W, Illidge TM. The future of anti-CD20 monoclonal antibodies: are we making progress? Blood 2011;117(11):2993-3001
   PubMed Web of Science ®Google Scholar
• Honeychurch J, Alduaij W, Azizyan M, et al. Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood 2012;119(15):3523-33
   PubMed Web of Science ®Google Scholar
• Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007;44(16):3823-37
   PubMed Web of Science ®Google Scholar
• Beurskens FJ, Lindorfer MA, Farooqui M, et al. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J Immunol 2012;188(7):3532-41
   PubMed Web of Science ®Google Scholar
• Hiraga J, Tomita A, Sugimoto T, et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 2009;113(20):4885-93
   PubMed Web of Science ®Google Scholar
• Small GW, McLeod HL, Richards KL. Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells. PeerJ 2013;1:e31
   Google Scholar
• Mishima Y, Terui Y, Takeuchi K, et al. The identification of irreversible rituximab-resistant lymphoma caused by CD20 gene mutations. Blood Cancer J 2011;1(4):e15
   Google Scholar
• Beers SA, French RR, Chan HT, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010;115(25):5191-201
   PubMed Web of Science ®Google Scholar
• Beum PV, Peek EM, Lindorfer MA, et al. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells. J Immunol 2011;187(6):3438-47
   PubMed Web of Science ®Google Scholar
• Awan FT, Kay NE, Davis ME, et al. Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. Blood 2009;113(3):535-7
   PubMed Web of Science ®Google Scholar
• Winter JN, Weller EA, Horning SJ, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006;107(11):4207-13
   PubMed Web of Science ®Google Scholar
• Cheadle EJ, Sidon L, Dovedi SJ, et al. The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab. Br J Haematol 2013;162(6):842-5
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013;31:51-72
   PubMed Web of Science ®Google Scholar
• Hilchey SP, Hyrien O, Mosmann TR, et al. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a “vaccinal effect” of rituximab. Blood 2009;113(16):3809-12
   PubMed Web of Science ®Google Scholar
• Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004;104(9):2635-42
   PubMed Web of Science ®Google Scholar
• Abes R, Gelize E, Fridman WH, Teillaud JL. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 2010;116(6):926-34
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008;8(1):34-47
   PubMed Web of Science ®Google Scholar
• Shields RL, Lai J, Keck R, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002;277(30):26733-40
   PubMed Web of Science ®Google Scholar
• Herting F, Friess T, Bader S, et al. Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma. Leuk Lymphoma 2014; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Niederfellner G, Mundigl O, Lifke A, et al. The Type Ii Cd20 antibody Ga101 differs from the type I Cd20 antibody rituximab in inducing differential gene expression profiles and by binding separate and functionally distinct Cd20 complexes on B cell lymphoma cell lines. Ann Oncol 2011;22:241-1
   Web of Science ®Google Scholar
• Salles G, Morschhauser F, Lamy T, et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 2012;119(22):5126-32
   PubMed Web of Science ®Google Scholar
• Sehn LH, Assouline SE, Stewart DA, et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood 2012;119(22):5118-25
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Cartron G, Lamy T, et al. Phase I study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia. Blood 2009;114(22):364-4
   Web of Science ®Google Scholar
• Cartron G, Morshhauser F, Thieblemont C. Results from a phase II study of obinutuzumab (GA101) monotherapy in relapsed/refractory chronic lymphocytic leukemia (CLL). Haematologica 2011;96:39
   PubMedGoogle Scholar
• Muller C, Murawski N, Wiesen MH, et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood 2012;119(14):3276-84
   PubMed Web of Science ®Google Scholar
• Davis TA, White CA, Grillo-Lopez AJ, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin’s lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999;17(6):1851-7
   PubMed Web of Science ®Google Scholar
• Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 1998;9(9):995-1001
   PubMed Web of Science ®Google Scholar
• Illidge TM, Bayne M, Brown NS, et al. Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood 2009;113(7):1412-21
   PubMed Web of Science ®Google Scholar
• Salles GA, Morschhauser F, Solal-Celigny P, et al. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol 2013;31(23):2920-6
   PubMed Web of Science ®Google Scholar
• Morschhauser FA, Cartron G, Thieblemont C, et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol 2013;31(23):2912-19
   PubMed Web of Science ®Google Scholar
• Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92(6):1927-32
   PubMed Web of Science ®Google Scholar
• Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000;18(2):317-24
   PubMed Web of Science ®Google Scholar
• Sehn L, Goy A, Offner F, et al. Randomized phase II trial comparing GA101 (obinutuzumab) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: preliminary analysis of the GAUSS study. Blood 2011;118:abstract 269
   Google Scholar
• Radford J, Davies A, Cartron G, et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood 2013;122(7):1137-43
   PubMed Web of Science ®Google Scholar
• Eichhorst BF, Busch R, Stilgenbauer S, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009;114(16):3382-91
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014;370(12):1101-10
   PubMed Web of Science ®Google Scholar
• Chang CH, Rossi EA, Goldenberg DM. Monoclonal antibodies targeting CD20. Mabs 2013;5(3):335-6
   PubMed Web of Science ®Google Scholar
• Hillmen P, Robak T, Janssens A, et al. Ofatumumab + chlorambucil versis chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the Phase III study complement 1 (OMB110911). Blood 2013;122(21):abstract 528
   Google Scholar
• Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Blood 2013;122(23):3723-34
   PubMed Web of Science ®Google Scholar